A 36-yr-old man with multiple endocrine neoplasia (MEN) type I had an
Acromegalic symptoms are occasionally induced by ectopic secretion of growth hormone (GH)-releasing hormone (GHRH) from tumors, which has been called the "ectopic GHRH syndrome" (Frohman et al ., 1980 ). In 1982 , Guillemin et al.(1982 and Rivier et al. (1982) independently isolated human pancreatic GHRH from pancreatic tumors that caused acromegaly, and subsequently the identity of this GHRH with human hypothalamic GHRH was demonstrated (Bohlen et al., 1983 , Ling et al., 1984 . The development of a radioimmunoassay (RIA) for measuring plasma immunoreactive (IR)-GHRH enabled us to differentiate the ectopic GHRH syndrome from so-called "classical acromegaly" and also clarify the mechanism of regulation of GH secretion in this pathophysiological state. Recent studies in some acromegalic patients with ectopic GHRH-producing tumor revealed that their plasma IR-GHRH concentrations were measurable in nanogram per ml (Thorner et al., 1984 , Penny et al., 1984 , Wilson et al., 1984 , von Werder et al., 1984 , Ch'ng et al., 1985 , Schulte et al., 1985 , von Gotteschalk et al., 1986 , Barkan et al., 1986 , Roth et al., 1986 , Boizel et al., 1987 .
We report the clinical features of a patient with multiple endocrine neoplasia (MEN) type I showing the ectopic GHRH syndrome.
His plasma IR-GHRH levels were considerably lower than those in the patients reported previously. We discuss here the pathophysiological role of GHRH in the regulation of GH secretion and in the formation of the acromegalic state. Extraction and Gel-filtration Chromatography of GHRH from plasma Each plasma sample was extracted with cold acetone/glacial acetic acid (100: 3, vol/vol) and petroleum ether (20 ml) to eliminate substances causing non-specific interference in the RIA system, and an additional tube containing the same amount of plasma extract but no anti-GHRH serum was also set up to evaluate the rate of non-specific binding of the tracer.
The extract prepared in the same manner from 15 ml of plasma obtained before surgery 1985 and May, 1986). graphy is shown in Fig. 3 . About 86% of the total GHRH-like immunoreactivity was eluted in the same position as synthetic GHRH (1-44) NH2.
The remainder was distributed in two small fractions; one near the void volume and the other in positions corresponding to molecular weights of 1000-2000. With another RIA system using anti-GHRH serum (RG-107) (Sano et al., 1986) , which recognizes GHRH (1-44) NH2 but not nonamidated GHRH fragments including GHRH (1-40) OH and GHRH (1-37) OH, GHRH-like immunoreactivity was also detected in the same position as synthetic peptide. release. The rebound surge of GH was not observed when somatostatin infusion was discontinued.
Neither IR-GHRH nor GH in the plasma showed any remarkable changes even in the slow wave stage during sleep.
As depicted in Fig. 7 , intravenous administration of TRH or an oral glucose load evoked a paradoxical increase in plasma GH and no apparent fluctuation in the plasma IR-GHRH concentration was observed in either test. On the other hand, a marked increase in plasma GH in response to arginine infusion or insulin hypoglycemia (blood glucose level; 109 to 60 mg/dl) was observed without any significant change in The effects of GHRH (1-44) NH2, TRH, glucose, arginine or insulin on plasma GH were examined one month and one year after removal of the pancreatic tumors, and results are shown in Fig. 8 . At one month, an apparent increase in plasma GH was observed in response to exogenous GHRH (1-44) NH2, but the rate of increase (4GH at 15 min, 46.5 ng/ml) was considerably lower than that before surgery (114 ng/ml). In addition, the paradoxical rise in plasma GH in response to TRH or glucose load was abolished after removal of the pancreatic tumors. As in the GHRH test, the responses of GH release to arginine infusion and insulin hypoglycemia (blood glucose concentration:
116 to 49 mg/dl) were less than before surgery. At twelve months, the responses of GH release in these endocrine tests (insulin hypoglycemia: 120 to 48 mg/dl) were similar to those one month after removal of the pancreatic tumors. et al., 1984) . The absence of a GH response to exogenous GHRH in patients with the ectopic GHRH syndrome was reported by Ch'ng et al.(1985) , Schulte et al.(1985) and Boizel et al.(1987) , suggesting that the somatotrophs in their patients were fully sensitized by etopic GHRH. In acromegalic patients this phenomenon indicates the presence of an ectopic GHRH-producing tumor. However, in our case, a marked rise in plasma GH was evoked by exogenous GHRH administration as observed by Barkan et al.(1986) , possibly because somatotrophs had not been stimulated maximally by ectopic GHRH secretion.
Therefore, patients with the ectopic GHRH syndrome may not show a consistent pattern of GH responsiveness to exogenous GHRH, and the determination of circulating GHRH should be necessary to confirm this syndrome.
Both somatostatin and SMS201-995 completely suppressed GH secretion, but unexpectedly, did not inhibit IR-GHRH release in our patient.
There are reports (von Werder et al., 1984 , Ch'ng et al., 1985 , Barkan et al., 1986 ) that the release of GHRH as well as GH in cases of metastatic GHRH-producing tumors was significantly suppressed by SMS201-995 and somatostatin when used as maintenance therapy. However, we demonstrated that the release of GHRH from monolayer cultures of pancreatic tumor cells from the patient was inhibited by incubation for 48 h with 10 nM somatostatin (unpublished observation). This discrepancy may be explained at least in part by the fact that the concentrations of somatostatin and SMS201-995 were not great enough to inhibit GHRH release from the tumor in vivo. gests that inhibition of hypothalamic GHRH release may occur through a negative feedback mechanism by excessive secretions of plasma GHRH and/or GH. On the other hand, recent studies by Hizuka et al. (1985) and Rochiccioli et al. (1986) demonstrated that continuous infusion of GHRH accelerated pulsatile GH secretion during sleep throughout the night in children with GH deficiency. Their studies suggest that continuous GHRH infusion may induce a periodic surge of hypothalamic somatostatin. If this is the case, patients with the ectopic GHRH syndrome may not show a periodic surge of hypothalamic somatostatin release. The paradoxical rise in the plasma GH concentration in response to TRH before surgery was abolished after removal of the GHRH-producing pancreatic tumor, as in the two cases reported by Thorner et al. (1982) and Schulte et al. (1985) , while only one reported case showed a diminished GH response to TRH after surgery (Boizel et al., 1987) . In an in vitro experiment by Borges et al. (1983) , the addition of TRH to the perifusate during GHRH perifusion of rat anterior pituitary cells resulted in further stimulation of GH release, suggesting that TRH can stimulate the pituitary after sensitization with a maximal concentration of GHRH. However, the paradoxical GH response after TRH could occur without maximal exposure of the somatotroph to GHRH, since such GH release was observed in our patient, who showed a further GH rise in response to exogenous GHRH. Simultaneously, abolishment of a paradoxical increase in plasma GH in response to an oral glucose load was also observed after surgery. These were diminished. Therefore, the effects of arginine and insulin on GH release were enhanced by ectopic secretion of GHRH.
In our patient, a paradoxical rise in plasma GH in response to TRH and an oral glucose load was observed more than 6 years before surgery, GHRH may have been released from his pancreatic tumor from that time. In fact, a moderate increase in circulating GHRH and a pancreatic tumor were detected 3 years previously. Interestingly, skull X-ray films showed that his sella turcica became gradually enlarged, and an enhanced brain CT scanning showed a "hypodense area" in the pituitary, which may have been due to bromocriptine therapy or infarction.
Therefore, ectopic secretion of GHRH from the pancreatic tumor stimulated his pituitary chronically (for more than 6 years), and resulted in development of an acromegalic state. His plasma GH and IGF-I did not return to normal until at least 12 months after surgery despite the fact that the plasma GHRH concentration became normal. The co-existence of an ectopic GH-producing tumor (Melmed et al., 1985) was excluded in this patient by immunohistochemistry and a biochemical study of his pancreatic tumors. Delay in recovery of the hypothalamopituitary axis seems to be unlikely, because all previous cases without pituitary tumors showed normalization of the plasma GH concentration soon after resection of the GHRH-producing tumor. Therefore, it is most probable that adenomatous changes occurred in his pituitary somatotrophs as in a case reported by Roth et al. (1986) . However, the possibility that pituitary adenoma may arise primarily independent from chronic stimulation by ectopic GHRH cannot be excluded, since the pituitary lesion is considered to be one of the phenotypes in MEN type I. tumor is unknown, but pituitary hyperplasia or adenoma could be induced by ectopic over-production and secretion of releasing hormone with biological activity, such as GHRH which acts on the pituitary. Indeed, in our case and others reported previously (Wilson et al., 1984 , Ch'ng et al., 1985 , Schulte et al., 1985 , Thorner et al., 1982 , Aida et al, 1977 , Caplan et al., 1978 , Sassolas et al., 1983 , ectopic secretion of GHRH released from the pancreatic tumor may have been involved in pituitary lesions. Recently, Roth et al. (1986) reported a case of somatotroph hyperplasia and acromegaly secondary to a pheochromocytoma secreting catecholamines and GHRH. Thus multiple endocrine syndromes including MEN may be caused at least in part by a single neoplasm, but further studies are required to establish their etiology.
